WO2007031329A3 - Verwendung eines kollagens xenogenen ursprungs - Google Patents

Verwendung eines kollagens xenogenen ursprungs Download PDF

Info

Publication number
WO2007031329A3
WO2007031329A3 PCT/EP2006/009004 EP2006009004W WO2007031329A3 WO 2007031329 A3 WO2007031329 A3 WO 2007031329A3 EP 2006009004 W EP2006009004 W EP 2006009004W WO 2007031329 A3 WO2007031329 A3 WO 2007031329A3
Authority
WO
WIPO (PCT)
Prior art keywords
collagen
xenogeneic origin
xenogeneic
origin
constrictions
Prior art date
Application number
PCT/EP2006/009004
Other languages
English (en)
French (fr)
Other versions
WO2007031329A2 (de
Inventor
Arne Briest
Marco Springer
Original Assignee
Ossacur Ag
Arne Briest
Marco Springer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ossacur Ag, Arne Briest, Marco Springer filed Critical Ossacur Ag
Publication of WO2007031329A2 publication Critical patent/WO2007031329A2/de
Publication of WO2007031329A3 publication Critical patent/WO2007031329A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Die Erfindung betrifft die Verwendung von Kollagen xenogenen Ursprungs zur Induktion und/oder Verstärkung der Neovaskularisierung sowie zur Prophylaxe und/oder Behandlung von Erkrankungen, die mit vaskulären Anomalien, insbesondere in Form von Verengungen und/ oder Verschlüssen, im Zusammenhang stehen, wobei das Kollagen einen Wirkstoffkomplex aufweist.
PCT/EP2006/009004 2005-09-15 2006-09-15 Verwendung eines kollagens xenogenen ursprungs WO2007031329A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005045671.5 2005-09-15
DE102005045671A DE102005045671A1 (de) 2005-09-15 2005-09-15 Verwendung eines Kollagens xenogenen Ursprungs

Publications (2)

Publication Number Publication Date
WO2007031329A2 WO2007031329A2 (de) 2007-03-22
WO2007031329A3 true WO2007031329A3 (de) 2007-07-12

Family

ID=37564137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/009004 WO2007031329A2 (de) 2005-09-15 2006-09-15 Verwendung eines kollagens xenogenen ursprungs

Country Status (2)

Country Link
DE (1) DE102005045671A1 (de)
WO (1) WO2007031329A2 (de)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001093880A1 (en) * 2000-06-05 2001-12-13 Yale University Production and use of microvessels in a fibronectin-containing gel
WO2002022157A2 (en) * 2000-09-14 2002-03-21 Transkaryotic Therapies, Inc. Injectable hybrid matrix mixtures
US20050064521A1 (en) * 2003-09-24 2005-03-24 Tunghai University In vitro assay for evaluation of angiogenic effects

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808402A (en) * 1987-05-29 1989-02-28 Northwestern University Method and compositions for modulating neovascularization
US4950483A (en) * 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
US6419920B1 (en) * 1995-10-25 2002-07-16 Trans Karyotic Therapies, Inc. Hybrid matrix implants and explants
US5962025A (en) * 1996-07-16 1999-10-05 The University Of Tennessee Research Corporation Method for treatment of systemic sclerosis and related fibrotic diseases
EP1019027A4 (de) * 1997-02-13 2004-05-12 Sulzer Biolog Inc Implantierbares kollagenhaltiges kittmaterial
US6328765B1 (en) * 1998-12-03 2001-12-11 Gore Enterprise Holdings, Inc. Methods and articles for regenerating living tissue
GB2344519B (en) * 1998-12-07 2004-05-19 Johnson & Johnson Medical Ltd Sterile therapeutic compositions
US20030007954A1 (en) * 1999-04-12 2003-01-09 Gail K. Naughton Methods for using a three-dimensional stromal tissue to promote angiogenesis
WO2000064954A1 (en) * 1999-04-22 2000-11-02 Vanderbilt University Polymeric encapsulation system promoting angiogenesis
US6506398B1 (en) * 2000-04-28 2003-01-14 Hosheng Tu Device for treating diabetes and methods thereof
US7153518B2 (en) * 2001-08-27 2006-12-26 Regeneration Technologies, Inc. Processed soft tissue for topical or internal application
TWI245634B (en) * 2001-12-28 2005-12-21 Ind Tech Res Inst Preparation of a biodegradable thermal-sensitive gel system
US8383158B2 (en) * 2003-04-15 2013-02-26 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001093880A1 (en) * 2000-06-05 2001-12-13 Yale University Production and use of microvessels in a fibronectin-containing gel
WO2002022157A2 (en) * 2000-09-14 2002-03-21 Transkaryotic Therapies, Inc. Injectable hybrid matrix mixtures
US20050064521A1 (en) * 2003-09-24 2005-03-24 Tunghai University In vitro assay for evaluation of angiogenic effects

Also Published As

Publication number Publication date
WO2007031329A2 (de) 2007-03-22
DE102005045671A1 (de) 2007-03-29

Similar Documents

Publication Publication Date Title
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
WO2007037849A3 (en) Compositions and methods for the intraocular transport of therapeutic agents
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
WO2007027761A3 (en) Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
WO2006013441A3 (en) Use of probiotic bacteria for the preparation of topical compositions for skin protection
WO2009091994A3 (en) Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
WO2008029276A3 (en) Compositions and methods for the treatment of ophthalmic disease
WO2011065982A3 (en) Polymorphisms associated with parkinson's disease
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
WO2010141648A3 (en) Artificial tears and therapeutic uses
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
WO2005091853A3 (en) Methods and compositions for treating il-13 related pathologies
MY172372A (en) Compositions and methods for lowering triglycerides
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
WO2005077093A3 (en) Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
WO2006096434A3 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
WO2006095029A3 (en) Di-polymer protein conjugates and processes for their preparation
WO2008060362A3 (en) Methods and compositions for the treatment of skin diseases and disorders
WO2012012718A3 (en) Manufacture of active highly phosphorylated human n-acetylgalactosamine-6-sulfatase and uses thereof
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
WO2007051785A3 (en) Use of sdf-1 for the treatment and/or prevention of neurological diseases
WO2006050826A3 (de) Behandlung von mastitis mit enrofloxacin
ATE433459T1 (de) Desoxo-nonadepsipeptide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06792086

Country of ref document: EP

Kind code of ref document: A2